Table 4. Summary of AEs . BV DTIC (n =... | American Society of Hematology

Table 4.

Summary of AEs

	BV+DTIC (n = 22)	BV+bendamustine (n = 20)
Any TEAE*	22 (100)	20 (100)
Treatment-related AEs	22 (100)	19 (95)
Grade ≥3 AEs	10 (45)	18 (90)
SAEs	4 (18)	13 (65)
AEs leading to treatment discontinuation	12 (55)	12 (60)
Deaths within 30 d of last dose	0	2 (10)†

	BV+DTIC (n = 22)	BV+bendamustine (n = 20)
Any TEAE*	22 (100)	20 (100)
Treatment-related AEs	22 (100)	19 (95)
Grade ≥3 AEs	10 (45)	18 (90)
SAEs	4 (18)	13 (65)
AEs leading to treatment discontinuation	12 (55)	12 (60)
Deaths within 30 d of last dose	0	2 (10)†

Data are presented as n (%) of patients.

TEAEs are presented and defined as newly occurring (not present at baseline) or worsening after first dose of investigational product.

Unrelated to study treatment.